JACOBS LEVY EQUITY MANAGEMENT, INC - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 192 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$15,281,460
-13.9%
1,307,225
-1.1%
0.09%
-10.8%
Q2 2023$17,758,017
-12.1%
1,321,281
+8.4%
0.10%
-17.7%
Q1 2023$20,210,921
+816.1%
1,218,994
+927.7%
0.12%
+726.7%
Q4 2022$2,206,202
+51.6%
118,613
+4.6%
0.02%
+25.0%
Q3 2022$1,455,000
-78.5%
113,423
-88.3%
0.01%
-76.9%
Q2 2022$6,779,000
-34.3%
967,060
-22.3%
0.05%
-24.6%
Q1 2022$10,321,000
+29.9%
1,245,030
+6.1%
0.07%
+30.2%
Q4 2021$7,947,000
+103.8%
1,173,849
+59.5%
0.05%
+103.8%
Q3 2021$3,900,000
-14.2%
735,920
-6.9%
0.03%
-16.1%
Q2 2021$4,543,000
-13.5%
790,149
-30.6%
0.03%
-22.5%
Q1 2021$5,249,000
+366.2%
1,138,611
+237.7%
0.04%
+300.0%
Q4 2020$1,126,000
+69.3%
337,214
+50.5%
0.01%
+42.9%
Q3 2020$665,000
-40.9%
224,074
-8.0%
0.01%
-41.7%
Q2 2020$1,126,000
+17.8%
243,650
-1.9%
0.01%0.0%
Q1 2020$956,000
+13.5%
248,416
+10.6%
0.01%
+50.0%
Q4 2019$842,000
-27.2%
224,665
+3.2%
0.01%
-42.9%
Q3 2019$1,156,000
+432.7%
217,700
+286.0%
0.01%
+366.7%
Q2 2019$217,000
-22.5%
56,400
+2.7%
0.00%
-25.0%
Q1 2019$280,000
+124.0%
54,900
-15.8%
0.00%
+100.0%
Q4 2018$125,000
-15.5%
65,200
+37.6%
0.00%0.0%
Q2 2018$148,000
+393.3%
47,400
+83.7%
0.00%
+100.0%
Q1 2016$30,00025,8000.00%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q2 2022
NameSharesValueWeighting ↓
TANAKA CAPITAL MANAGEMENT INC 148,281$2,4587.14%
GABLES CAPITAL MANAGEMENT INC. 409,080$6,782,5464.74%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 10,355,099$171,687,5413.83%
JW Asset Management, LLC 563,392$9,341,0393.58%
Quantedge Capital Pte Ltd 324,700$5,383,5262.10%
Paradiem, LLC 236,628$3,923,2921.22%
SummerHaven Investment Management, LLC 100,592$1,667,8150.97%
Capital Impact Advisors, LLC 46,096$764,2720.94%
Yorktown Management & Research Co Inc 50,000$829,0000.89%
Seaport Global Advisors, LLC 15,598$258,6150.82%
View complete list of CATALYST PHARMACEUTICALS INC shareholders